Small cell undifferentiated bronchogenic carcinoma: Current status with emphasis upon the role of chemotherapy

Paul S. Johnson, John F. Foley, Anne Kessinger, Henry M. Lemon

Research output: Contribution to journalArticle


Current opinions concerning tumor biology and clinical characteristics of small cell undifferentiated bronchogenic carcinoma are reviewed. Special emphasis is placed upon chemotherapy for this lung cancer subtype and presently achievable response rates and survival times are presented. A series of 16 patients with small cell undifferentiated bronchogenic carcinoma is also presented. All patients were given cyclophosphamide, methotrexate, vincristine, and procarbazine as treatment for this neoplasm. Sixty‐eight percent of patients responded and the survival time in partial responders was 33.4+ weeks as compared to 13.7 weeks with nonresponders. These data correlate well with the previous data of Alberto et al [Alberto P, Brunner KW, Martz G, Obrect JP: Cancer 38:2208–2216, 1976], who investigated the same agents for this tumor, but at higher dosages.

Original languageEnglish (US)
Pages (from-to)549-557
Number of pages9
JournalJournal of Surgical Oncology
Issue number6
StatePublished - 1978



  • lung cancer
  • oat cell carcinoma
  • small cell undifferentiated bronchogenic carcinoma
  • therapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this